Finance

Lists
Why is RCUS down 3.13%?
Dive Deeper
RCUS:NYSE
Arcus Biosciences Inc
$24.44
-3.13%
(-0.79) 1D
$24.54
+0.41% (+0.10)
After hours
Closed: Oct 2, 4:00:07 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCUS...
Open
$25.48
High
$25.58
Low
$24.09
Mkt. cap
3.11B
Avg. vol.
1.54M
Volume
1.04M
52-wk high
$31.74
52-wk low
$13.21
EPS
-$3.90
Beta
0.94
Shares outstanding
127.33M
No. of employees
601
Open
$25.48
High
$25.58
Low
$24.09
Mkt. cap
3.11B
Avg. vol.
1.54M
Volume
1.04M
52-wk high
$31.74
52-wk low
$13.21
EPS
-$3.90
Beta
0.94
Shares outstanding
127.33M
No. of employees
601
News stories
From web sources and news partners
About Arcus Biosciences Inc
CEO-
Employees601
Founded2015
Headquarters-
SectorBiotechnology
Websitearcusbio.com
Analyst ratings
Based on 11 analysts giving stock ratings to RCUS in the past 3 months
Buy
Buy
8
Hold
3
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for RCUS in the last 3 months.
Highest
Current $24.44
$47.00 (+92.31%)
Average
$38.60 (+57.94%)
Lowest
$23.00 (-5.89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Driscoll
Wedbush
Buy
Maintained
$43.00
+75.9%
09/30/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$46.00
+88.2%
09/27/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$45.00
+84.1%
09/25/2026
Tara Bancroft
TD Cowen
Buy
Initiated
-
-
09/16/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$45.00
+84.1%
09/09/2026
Supawat Thongthip
Truist Financial
Buy
Reiterated
$40.00
+63.7%
09/08/2026
Jason Zemansky
Bank of America Securities
Hold
Reiterated
$29.00
+18.7%
08/11/2026
Terence Flynn
Morgan Stanley
Hold
Reiterated
$23.00
-5.9%
08/10/2026
Richard Law CFA
Goldman Sachs
Buy
Reiterated
$42.00
+71.8%
08/10/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$47.00
+92.3%
08/05/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Reiterated
$26.00
+6.4%
08/06/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$47.00
+92.3%
06/10/2026
Gregory Renza
Truist Financial
Buy
Initiated
$35.00
+43.2%
05/18/2026
Daina Graybosch
Leerink Partners
Buy
Maintained
$47.00
+92.3%
04/20/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
-
-
03/02/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
$30.00
+22.7%
02/27/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.72 / -$0.81
+11.58%beat
Revenue / Est. (USD)
41.00M / 21.98M
+86.52%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
26.00M
33.00M
17.00M
41.00M
Cost of goods sold
141.00M
121.00M
122.00M
113.00M
Cost of revenue
141.00M
121.00M
122.00M
113.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.00M
26.00M
29.00M
24.00M
Operating expense
27.00M
26.00M
29.00M
24.00M
Total operating expenses
168.00M
147.00M
151.00M
137.00M
Operating income
-142.00M
-114.00M
-134.00M
-96.00M
Other non operating income
-
-
-
-
EBT including unusual items
-135.00M
-106.00M
-128.00M
-91.00M
EBT excluding unusual items
-135.00M
-106.00M
-128.00M
-91.00M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-135.00M
-106.00M
-128.00M
-91.00M
Net profit margin
-519.23%
-321.21%
-752.94%
-221.95%
Earnings per share
-1.27
-0.89
-1.02
-0.72
Interest and investment income
10.00M
10.00M
9.00M
8.00M
Interest expense
-3.00M
-2.00M
-3.00M
-3.00M
Net interest expenses
7.00M
8.00M
6.00M
5.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-140.00M
-111.00M
-132.00M
-93.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps